Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †

SIMPLE SUMMARY: Trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included in these trials. The aim of this study was to describe the treatment patterns and outcomes of “real-world” older patient...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancers (Basel)
Main Authors: de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A. M., Suijkerbuijk, Karlijn P. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., de Groot, Jan-Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Portielje, Johanneke E. A., Kapiteijn, Ellen W.
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8201158/
https://ncbi.nlm.nih.gov/pubmed/34198950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112826
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים